Treatment of hepatitis C in liver transplant patients: Interferon out, direct antiviral combos in

Liver Transplantation

Volumn 21, Issue 4, 2015, Pages 423-434

  Price, Jennifer C ^a   Terrault, Norah A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INTERFERON;

DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG TOLERABILITY; GRAFT SURVIVAL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; LIVER TRANSPLANTATION; NONHUMAN; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT RESPONSE; UNITED STATES; COMBINATION DRUG THERAPY; COMPLICATION; END STAGE LIVER DISEASE; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS; RECURRENT DISEASE; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; END STAGE LIVER DISEASE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER CIRRHOSIS; RECURRENCE; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84925878769     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.24080     Document Type: Review

References (72)

1. World Health Organization. Hepatitis C. http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index4.html#incidence. Accessed on July 2014.
2. Kim WR, Stock PG, Smith JM, Heimbach JK, Skeans MA, Edwards EB, et al. OPTN/SRTR 2011 annual data report: liver. Am J Transplant 2013; 13 (suppl 1): 73-102.
3. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR,. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-896.
4. Berenguer M, Schuppan D,. Progression of liver fibrosis in post-transplant hepatitis C: Mechanisms, assessment and treatment. J Hepatol 2013; 58: 1028-1041.
5. Narang TK, Ahrens W, Russo MW,. Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver Transpl 2010; 16: 1228-1235.
6. Berenguer M, Roche B, Aguilera V, Duclos-Vallée JC, Navarro L, Rubín A, et al. Efficacy of the retreatment of hepatitis C virus infections after liver transplantation: role of an aggressive approach. Liver Transpl 2013; 19: 69-77.
7. Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, Ray C,. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42: 255-262.
8. Tekin F, Gunsar F, Karasu Z, Akarca U, Ersoz G,. Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics. Aliment Pharmacol Ther 2008; 27: 1081-1085.
9. Osinusi A, Meissner EG, Lee YJ, Bon D, Heytens L, Nelson A, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013; 310: 804-811.
10. Sulkowski MS, Rodriguez-Torres M, Lalezari JP, Fessel WJ, Mounzer K, Shuhart MC, et al. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients coinfected with HIV (PHOTON-1). Hepatology 2013; 58 (Suppl): 86A. Paper presented at: American Association for the Study of Liver Diseases Annual Meeting 2013; Nov 1-5, 2013; Washington, DC.
11. Lalezari JP, Nelson DR, Hyland RH, Lin M, Rossi SJ, Symonds WT, et al. Once-daily sofosbuvir plus ribavirin for 12 and 24 weeks in treatment-naïve patients with HCV infection: the QUANTUM study. J Hepatology 2013; 58: S346. In: Program and abstracts of the European Association for the Study of the Liver 48th Annual Meeting; April 24-28, 2013; Amsterdam, the Netherlands.
12. Gane EJ, Stedman CA, Hyland RH, Pang PS, Ding X, Symonds WT, et al. All-oral sofosbuvir-based 12-weeks regimens for the treament of chronic HCV infection: the Electron study. Program and abstracts of the 48th Annual Meeting of the European Association for the Study of the Liver. April 24-28, 2013; Amsterdam, the Netherlands. Abstract O12.
13. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naïve patients: the COSMOS randomised study. Lancet 2014; 384: 1756-1765.
14. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al.; for ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-1898.
15. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al.; for ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-1493.
16. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370: 1973-1982.
17. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1594-1603.
18. Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng CY, et al.; for HALLMARK-DUAL Study Team. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014; 384: 1597-1605.
19. Muir A, Poordad F, Lalezari JP, Everson GT, Dore GJ, Kwo P, et al. All-oral fixed dose combination therapy with daclatasvir/asunaprevir/BMS-791325, +/- ribavirin, for patients with chronic HCV genotype 1 infection and compensated cirrhosis: UNITY-2 phase 3 SVR12 results. In: Program and abstracts of the 65th Annual Meeting of the American Association for the Study of Liver Diseases; November 7-11, 2014; Boston, MA. Abstract LB-2. Hepatology 2014;60 Suppl.
20. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al.; for AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211-221.
21. Lawitz E, Gane EJ, Pearlman B, Tam E, Ghesquiere W, Guyader D, et al. Efficacy and safety of MK-5172 and MK-8742 +/- ribavirin in hepatitis C genotype 1 infected patients wtih cirrhosis or previous null response: final results of the C-WORTHY study (parts A and B). In: Program and abstracts of the 65th Annual Meeting of the American Association for the Study of Liver Diseases; November 7-11, 2014; Boston, MA. Abstract 196. Hepatology 2014; 60; number 4 Supplement; 91A.
22. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al.; for POSITRON Study; FUSION Study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-1877.
23. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al.; for VALENCE Investigators. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993-2001.
24. Everson GT, Tran TT, Towner WJ, Davis MN, Wyles D, Nahass R, et al. Safety and efficacy of treatment with the interferon-free, ribavirin-free combination of sofosbuvir+ GS-5816 for 12 weeks in treatment naïve patients with genotype 1-6 HCV infection. In: Program and abstracts of the 49th Annual Meeting of the European Association for the Study of the Liver; April 9-13, 2014; London, England. Abstract O111. J Hepatol 2014;60 (Suppl): S46.
25. Pianko S, Flamm SL, Shiffman ML, Kumar S, Strasser SI, Dore GJ, et al. High efficacy of treatment with sofosbuvir+GS-5816 +/- ribavirin for 12 weeks in treatment experienced patients with genotype 1 or 3 HCV infection. In: Program and abstracts of the 65th Annual Meeting of the American Association for the Study of Liver Diseases; November 7-11, 2014; Boston, MA. Abstract 197. Hepatology 2014;60(Number 4 Suppl):86A.
26. Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, et al. All-oral 12-week combination treatment with daclatasvir (DCV) and sofosbuvir (sof) in patients infected with HCV genotype (GT) 3: ALLY-3 phase 3 study. In: Program and abstracts of the 65th Annual Meeting of the American Association for the Study of Liver Diseases; November 7-11, 2014; Boston, MA. Abstract LB-3.
27. Sovaldi [package insert]. Gilead Sciences: Foster City, CA, 2013.
28. American Association for the Study of Liver Diseases, IDSA, IAS-USA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed on March 2015.
29. Thomas RM, Brems JJ, Guzman-Hartman G, Yong S, Cavaliere P, Van Thiel DH,. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003; 9: 905-915.
30. Forns X, García-Retortillo M, Serrano T, Feliu A, Suarez F, de la Mata M, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39: 389-396.
31. Everson GT, Terrault NA, Lok AS, Rodrigo del R, Brown RS Jr, Saab S, et al.; for Adult-to-Adult Living Donor Liver Transplantation Cohort Study. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology 2013; 57: 1752-1762.
32. Carriõn JA, Martínez-Bauer E, Crespo G, Ramírez S, Pérez-del-Pulgar S, García-Valdecasas JC, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol 2009; 50: 719-728.
33. Massoumi H, Elsiesy H, Khaitova V, Peterson B, Norkus E, Grewal P, et al. An escalating dose regimen of pegylated interferon and ribavirin in HCV cirrhotic patients referred for liver transplant. Transplantation 2009; 88: 729-735.
34. Hézode C, Fontaine H, Dorival C, Zoulim F, Larrey D, Canva V, et al.; for CUPIC Study Group. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 2014; 147: 132-142.
35. Saxena V, Manos MM, Yee HS, Catalli L, Wayne E, Murphy RC, et al. Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis. Aliment Pharmacol Ther 2014; 39: 1213-1224.
36. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-1887.
37. Curry MP, Forns X, Chung RT, Terrault NA, Brown R Jr, Fenkel JM, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 2015; 148: 100-107.
38. D'Ambrosio R, Aghemo A, Rumi MG, Ronchi G, Donato MF, Paradis V, et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology 2012; 56: 532-543.
39. Mallet V, Gilgenkrantz H, Serpaggi J, Verkarre V, Vallet-Pichard A, Fontaine H, Pol S,. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008; 149: 399-403.
40. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella G, Denning J, et al.; for Italian Association of the Study of the Liver Disease (AISF). Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. J Hepatol 2014;60(suppl):S28.
41. Cardoso AC, Moucari R, Figueiredo-Mendes C, Ripault MP, Giuily N, Castelnau C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010; 52: 652-657.
42. Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, et al.; HALT-C Trial Group. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52: 833-844.
43. Fernández-Rodríguez CM, Alonso S, Martinez SM, Forns X, Sanchez-Tapias JM, Rincõn D, et al.; for Group for the Assessment of Prevention of Cirrhosis Complications and Virological Response (APREVIR). Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response. Am J Gastroenterol 2010; 105: 2164-2172.
44. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-2593.
45. Iacobellis A, Siciliano M, Perri F, Annicchiarico BE, Leandro G, Caruso N, et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007; 46: 206-212.
46. Hézode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890. J Hepatol 2013; 59: 434-441.
47. Olysio [package insert]. Janseen Therapeutics: Titusville, NJ, 2013.
48. Forns X, Prieto M, Charlton M, McHutchinson JG, Symonds WT, Brainard D, Denning J, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C including fibrosing cholestatic hepatitis following liver transplantation. In: Program and abstracts of the 49th Annual Meeting of the European Association for the Study of the Liver; April 9-13, 2014; London, England. Abstract O62. J Hepatol 2014;60(Suppl):S26.
49. Afdhal N, Everson G, Calleja JL, McCaughan G, Symonds WT, Brainard D, et al. Sofosbuvir and ribavirin for the treatment chronic HCV with cirrhosis and portal hypertension with and without decompensation: early virologic response and safety. In: Program an d abstracts of the 49th Annual Meeting of the European Association for the Study of the Liver; April 9-13, 2014; London, England. Abstract O68.
50. Flamm SL, Everson GT, Charlton M, Denning JM, Arterburn S, Brandt-Sarif T, et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study. Program and abstracts of the 65th Annual Meeting of the American Association for the Study of Liver Diseases; November 7-11, 2014; Boston, MA, Abstract 239. Hepatology 2014;60(Number 4 Suppl):91A.
51. Gane EJ, Hyland RH, An D, Pang PS, Symonds WT, McHutchison JG, Stedman CA, et al. Sofosbuvir/ledipasvir fixed dose combination is safe and effective in difficult-to-treat populations including genotype-3 patients, decompensated genotype-1 patients, and genotype-1 patients with prior sofosbuvir treatment experience. Program and abstracts of the 49th Annual Meeting of the European Association for the Study of the Liver; April 9-13, 2014; London, England. Abstract 06.
52. Wiesner RH, Sorrell M, Villamil F,; for International Liver Transplantation Society Expert Panel. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9 (11): S1-S9.
53. Berenguer M, Palau A, Aguilera V, Rayõn JM, Juan FS, Prieto M,. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008; 8: 679-687.
54. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K,. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006; 6: 1586-1599.
55. Berenguer M,. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274-287.
56. Xirouchakis E, Triantos C, Manousou P, Sigalas A, Calvaruso V, Corbani A, et al. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. J Viral Hepat 2008; 15: 699-709.
57. Burton JR Jr, O'Leary JG, Verna EC, Saxena V, Dodge JL, Stravitz RT, et al. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. J Hepatol 2014; 61: 508-514.
58. Pungpapong S, Aqel BA, Koning L, Murphy JL, Henry TM, Ryland KL, et al. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl 2013; 19: 690-700.
59. Hulskotte E, Gupta S, Xuan F, van Zutven M, O'Mara E, Feng HP, et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology 2012; 56: 1622-1630.
60. Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X,. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 20-27.
61. O'Leary JG, McKenna GJ, Klintmalm GB, Davis GL,. Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients. Liver Transpl 2013; 19: 463-465.
62. Charlton M, Gane E, Manns MP, Brown RS Jr, Curry MP, Kwo PY, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015; 148: 108-117.
63. Reddy KR, Everson GT, Flamm SL, Denning JM, Arterburn S, Brandt-Sarif T, et al. Ledipasvir-sofosbuvir with ribavirin for the treatment of HCV in patients with post transplant recurrence: preliminary results of a prospective, multicenter study. In: Program and abstracts of the 65th Annual Meeting of the American Association for the Study of Liver Diseases; November 7-11, 2014; Boston, MA. Abstract 8.
64. Mantry P, Kwo P, Coakley E, Te H, Vargas H, Brown Jr. RS, et al. CORAL-I [M12-999]: ABT-450/r/ombitasvir (ABT-267)+dasabuvir (ABT-333)+ribavirin in liver transplant recipients with recurrent HCV genotype 1 infection. In: Program and abstracts of the World Transplant Congress; July 26-31, 2014; San Francisco, CA. Abstract 1325.
65. Castellares C, Barreiro P, Martín-Carbonero L, Labarga P, Vispo ME, Casado R, et al. Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome. J Viral Hepat 2008; 15: 165-172.
66. Brown RS, Reddy K, O'Leary JG, Kuo A, Morelli G, Stratvitz R, et al. Safety and efficacy of new DAA-based therapy for hepatitis C post-transplant: interval results from the HCV-TARGET longitudinal, observational study. In: Program and abstracts of the 65th Annual Meeting of the American Association for the Study of Liver Diseases; November 7-11, 2014; Boston, MA. Abstract LB-4.
67. Pungpapong S, Werner KT, Aqel B, Leise MD, Murphy JL, Henry TM, et al. Multicenter experience using sofosbuvir and simeprevir with/without ribavirin to treat HCV genotype 1 after liver transplantation. In: Program and abstracts of the 65th Annual Meeting of the American Association for the Study of Liver Diseases; November 7-11, 2014; Boston, MA. Abstract 9.
68. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS,. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526.
69. Janssen R&D (Posted 2013). A study of pharmacokinetics, efficacy, safety, tolerability, of the combination of simeprevir (TMC435), daclatasvir (BMS-790052), and ribavirin (RBV) in patients with recurrent chronic hepatitis C genotype 1b infection after orthotopic liver transplantation (NCT01938625). http://www.clinicaltrials.gov/ct2/show/NCT01938625. Accessed September 5, 2014.
70. Pellicelli AM, Montalbano M, Lionetti R, Durand C, Ferenci P, D'Offizi G, et al. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given late. Dig Liver Dis 2014; 46: 923-927.
71. Fontana RJ, Hughes EA, Bifano M, Appelman H, Dimitrova D, Hindes R, Symonds WT,. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. Am J Transplant 2013; 13: 1601-1605.
72. Leroy V, Dumortier J, Coilly A, Sebagh M, Fougerou-Leurent C, Radenne S, et al. High rates of virological response and major clinical improvement during sofosbuvir and daclatasvir-based regiments for the treatment of fibrosing cholestatic HCV-recurrence after liver transplantation: the ANRS CO23 CUPILT study. In: Program and abstracts of the 65th Annual Meeting of the American Association for the Study of Liver Diseases; November 7-11, 2014; Boston, MA. Abstract 21. Hepatology 2014;60:Number 4 Suppl:53A.